BioCentury | Sep 30, 2020
Product Development

Partner Amgen becomes investor as Carmot pushes diabetes therapies ahead with $47M series C

...has joined the syndicate of investors backing Carmot...
...development. Co-founder and CEO Stig Hansen believes Carmot’s...
...cysteine targets because cysteine-reactive compounds are inherently unstable.Carmot...
BioCentury | Feb 16, 2018
Strategy

Pfizer’s chemistry machine

...platform for automated nanomole-scale reaction screening and micromole-scale synthesis in flow.” Science (2018) Michael Leviten, Senior Writer Carmot Therapeutics Inc. Pfizer...
BioCentury | Aug 11, 2017
Tools & Techniques

K follows C in chemoproteomics

...have otherwise noticed that you could go after just using traditional chemical methodology.” Daniel Erlanson, Carmot...
...the enzymes that mediate post translational modifications. Daniel Erlanson, co-founder and VP of Chemistry at Carmot Therapeutics Inc....
...and Institutions Mentioned Abide Therapeutics Inc., San Diego, Calif. AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Carmot Therapeutics Inc....
BioCentury | Jul 11, 2016
Company News

Carmot, Genentech, Roche deal

...Carmot and Roche’s Genentech unit partnered to use Carmot’s Chemotype Evolution technology to identify drug candidates...
...to identify drug candidates. Genentech will be responsible for development and commercialization of the candidates. Carmot...
...Carmot declined to disclose financial terms. Chemotype Evolution generates leads by linking a member of Carmot’s...
BioCentury | Jul 7, 2016
Company News

Carmot, Genentech in discovery deal

...San Francisco, Calif) and the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) partnered to use Carmot's...
...identify novel drug candidates. Genentech will be responsible for development and commercialization of identified candidates. Carmot...
...royalties. Genentech declined to disclose targets or indications to be explored under the deal, and Carmot...
BioCentury | Jan 20, 2014
Company News

Amgen, Carmot deal

...Carmot and Amgen partnered to use Carmot's Chemotype Evolution fragment-based lead discovery technology to discover novel...
...lead discovery technology to discover novel drug leads for two undisclosed targets selected by Amgen. Carmot...
...will collaborate to identify and optimize drug candidates. Amgen will be responsible for clinical development. Carmot...
BioCentury | Jan 15, 2014
Company News

Carmot, Amgen in discovery deal

...Carmot Therapeutics Inc. (San Francisco, Calif.) and Amgen Inc. (NASDAQ:AMGN) partnered to use Carmot's Chemotype Evolution...
...lead discovery technology to discover novel drug leads for two undisclosed targets selected by Amgen. Carmot...
...will collaborate to identify and optimize drug candidates. Amgen will be responsible for clinical development. Carmot...
BioCentury | Jan 3, 2011
Financial News

Carmot completes venture financing

Carmot Therapeutics Inc. , San Francisco, Calif. Business: Neurology, Metabolic Date completed: 12/20/10 Type: Venture financing Raised: Not disclosed Investors: Leader Ventures WIR Staff Neurology...
BioCentury | Feb 15, 2010
Company News

Carmot, Sunesis deal

...Carmot received an exclusive license to Sunesis' Chemotype Evolution fragment-based lead discovery technology. Carmot will use...
...Sunesis will retains rights for use in its internal programs. Further terms were not disclosed. Carmot Therapeutics Inc....
BioCentury | Jul 20, 2009
Company News

Carmot, CV Ingenuity, FibroGen, Gemmus Pharma, Osprey Pharmaceuticals U.S.A., Solidus, California Institute for Quantitative Biosciences other news

...services, plus office and laboratory space at FibroGen's headquarters in Mission Bay. The companies include: Carmot...
Items per page:
1 - 10 of 10
BioCentury | Sep 30, 2020
Product Development

Partner Amgen becomes investor as Carmot pushes diabetes therapies ahead with $47M series C

...has joined the syndicate of investors backing Carmot...
...development. Co-founder and CEO Stig Hansen believes Carmot’s...
...cysteine targets because cysteine-reactive compounds are inherently unstable.Carmot...
BioCentury | Feb 16, 2018
Strategy

Pfizer’s chemistry machine

...platform for automated nanomole-scale reaction screening and micromole-scale synthesis in flow.” Science (2018) Michael Leviten, Senior Writer Carmot Therapeutics Inc. Pfizer...
BioCentury | Aug 11, 2017
Tools & Techniques

K follows C in chemoproteomics

...have otherwise noticed that you could go after just using traditional chemical methodology.” Daniel Erlanson, Carmot...
...the enzymes that mediate post translational modifications. Daniel Erlanson, co-founder and VP of Chemistry at Carmot Therapeutics Inc....
...and Institutions Mentioned Abide Therapeutics Inc., San Diego, Calif. AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Carmot Therapeutics Inc....
BioCentury | Jul 11, 2016
Company News

Carmot, Genentech, Roche deal

...Carmot and Roche’s Genentech unit partnered to use Carmot’s Chemotype Evolution technology to identify drug candidates...
...to identify drug candidates. Genentech will be responsible for development and commercialization of the candidates. Carmot...
...Carmot declined to disclose financial terms. Chemotype Evolution generates leads by linking a member of Carmot’s...
BioCentury | Jul 7, 2016
Company News

Carmot, Genentech in discovery deal

...San Francisco, Calif) and the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) partnered to use Carmot's...
...identify novel drug candidates. Genentech will be responsible for development and commercialization of identified candidates. Carmot...
...royalties. Genentech declined to disclose targets or indications to be explored under the deal, and Carmot...
BioCentury | Jan 20, 2014
Company News

Amgen, Carmot deal

...Carmot and Amgen partnered to use Carmot's Chemotype Evolution fragment-based lead discovery technology to discover novel...
...lead discovery technology to discover novel drug leads for two undisclosed targets selected by Amgen. Carmot...
...will collaborate to identify and optimize drug candidates. Amgen will be responsible for clinical development. Carmot...
BioCentury | Jan 15, 2014
Company News

Carmot, Amgen in discovery deal

...Carmot Therapeutics Inc. (San Francisco, Calif.) and Amgen Inc. (NASDAQ:AMGN) partnered to use Carmot's Chemotype Evolution...
...lead discovery technology to discover novel drug leads for two undisclosed targets selected by Amgen. Carmot...
...will collaborate to identify and optimize drug candidates. Amgen will be responsible for clinical development. Carmot...
BioCentury | Jan 3, 2011
Financial News

Carmot completes venture financing

Carmot Therapeutics Inc. , San Francisco, Calif. Business: Neurology, Metabolic Date completed: 12/20/10 Type: Venture financing Raised: Not disclosed Investors: Leader Ventures WIR Staff Neurology...
BioCentury | Feb 15, 2010
Company News

Carmot, Sunesis deal

...Carmot received an exclusive license to Sunesis' Chemotype Evolution fragment-based lead discovery technology. Carmot will use...
...Sunesis will retains rights for use in its internal programs. Further terms were not disclosed. Carmot Therapeutics Inc....
BioCentury | Jul 20, 2009
Company News

Carmot, CV Ingenuity, FibroGen, Gemmus Pharma, Osprey Pharmaceuticals U.S.A., Solidus, California Institute for Quantitative Biosciences other news

...services, plus office and laboratory space at FibroGen's headquarters in Mission Bay. The companies include: Carmot...
Items per page:
1 - 10 of 10